On May 22, 2025, Axsome Therapeutics (AXSM, Financial) received a reaffirmed "Buy" rating from HC Wainwright & Co. The investment firm, represented by analyst Raghuram Selvaraju, maintained its price target for Axsome Therapeutics at $180.00 USD.
The reiteration of the "Buy" rating suggests continued confidence in Axsome Therapeutics' (AXSM, Financial) market potential and business strategy. The consistent price target indicates that HC Wainwright & Co. sees stable growth prospects for the pharmaceutical company.
Investors and market watchers should note that Axsome Therapeutics (AXSM, Financial) remains a recommended investment according to HC Wainwright & Co., with the current price target unchanged from its prior level at $180.00 USD. The rating remains steady, suggesting that the company's financial health and market performance continue to align with analyst expectations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Axsome Therapeutics Inc (AXSM, Financial) is $176.53 with a high estimate of $210.00 and a low estimate of $146.00. The average target implies an upside of 66.92% from the current price of $105.76. More detailed estimate data can be found on the Axsome Therapeutics Inc (AXSM) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, Axsome Therapeutics Inc's (AXSM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Axsome Therapeutics Inc (AXSM, Financial) in one year is $249.64, suggesting a upside of 136.04% from the current price of $105.76. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Axsome Therapeutics Inc (AXSM) Summary page.
